Clincosm LogoSign in Get a demo

overall survival

Showing 1 - 25 of 32
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Overall Survival, Progression-free Survival, Cost Trial (Microwave Ablation)

Completed
  • Overall Survival
  • +2 more
  • Microwave Ablation
  • (no location specified)
Apr 1, 2023

Objective Response, Overall Survival Trial in Beijing (VIA combination treatment)

Completed
  • Objective Response
  • Overall Survival
  • VIA combination treatment
  • Beijing, China
    Peking University People's Hospital
Dec 9, 2022

Lung Cancer, Surgery, Blood Pressure Management Trial in Beijing (Dexamethasone, Targeted blood pressure management, Placebo)

Recruiting
  • Lung Cancer
  • +5 more
  • Beijing, Beijing, China
    Department of Anesthesiology and Critical Care Medicine, Peking
Aug 8, 2022

Progression Free Survival, Overall Survival, Maintenance Trial (Ixazomib DX/Lenalidomide DX)

Not yet recruiting
  • Progression Free Survival
  • +2 more
  • Ixazomib DX/Lenalidomide DX
  • (no location specified)
Jul 27, 2022

dataBase for Analysis of Rectal Cancer Oncological Results

Recruiting
  • Rectal Cancer
  • +4 more
  • Krakow, Malopolska, Poland
    1st Department of General Surgery
Jul 3, 2022

Overall Survival Trial in Qingdao (Rituximab + zanubrutinib + lenalidomide)

Recruiting
  • Overall Survival
  • Rituximab + zanubrutinib + lenalidomide
  • Qingdao, Shandong, China
    Qingdao central Hospital
May 22, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Chromosomal Instability in Ovarian Cancer

Recruiting
  • Epithelial Ovarian Cancer
  • +7 more
  • Testing for chromosomal instability (CIN)
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Overall Survival Trial in Qingdao (Anlotinib, PD-1 inhibitor)

Recruiting
  • Overall Survival
  • Anlotinib, PD-1 inhibitor
  • Qingdao, Shandong, China
  • +1 more
Feb 23, 2022

Disease Free Survival, Overall Survival, Pancreatic Cancer Trial in Milan (use of targeted drugs such as aspirin, B-Blockers,

Recruiting
  • Disease Free Survival
  • +2 more
  • use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins
  • Milan, Italy
    IRCCS San Raffaele
Mar 7, 2022

Elderly, Surgery, Intensive Care Unit Trial in Beijing (Dexmedetomidine, Placebo)

Recruiting
  • Elderly
  • +4 more
  • Beijing, Beijing, China
    Peking University First Hospital
Sep 14, 2021

Pancreatic Cancer, Surgery, Epidural Block Trial in Beijing (Epidural block, Dexamethasone)

Recruiting
  • Pancreatic Cancer
  • +4 more
  • Beijing, Beijing, China
    Peking University First Hospital
Jul 5, 2021

Overall Survival, Tumor Responses Trial in Taichung (Atorvastatin 10mg, Placebo Oral Tablet)

Terminated
  • Overall Survival
  • Tumor Responses
  • Atorvastatin 10mg
  • Placebo Oral Tablet
  • Taichung, Taiwan
    Taichung Veterans General Hospital
Mar 14, 2021

Event-free Survival, Overall Survival, Local-recurrence Free Survival Trial in Beijing (Cisplatin)

Completed
  • Event-free Survival
  • +3 more
  • Beijing, Beijing, China
    Peking University People's Hospital
Jan 2, 2021

Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and

Recruiting
  • Recurrent Cervical Carcinoma
  • +6 more
  • Combination of nimotuzumab and radiotherapy
  • Beijing, Beijing, China
    Lei Li
Dec 18, 2020

Pancreatic Metastases From Renal Cell Carcinoma

Unknown status
  • Surgical Procedure
  • +2 more
    • Badajoz, Spain
      Gerardo Blanco-Fernández
    Nov 2, 2020

    Progression-free Survival, Overall Survival, Toxicity Trial in Beijing (pegylated liposomal doxorubicin, pirarubicin)

    Withdrawn
    • Progression-free Survival
    • +2 more
    • Beijing, China
      Peking University People's Hospital
    May 15, 2020

    Progression-free Survival, Overall Survival, Clinical Benefit Rate Trial in Beijing (Apatinib, SHR-1210)

    Completed
    • Progression-free Survival
    • +3 more
    • Beijing, China
    • +1 more
    May 15, 2020

    Quality of Life in Cervical Cancer Patients

    Recruiting
    • Quality of Life
    • +9 more
    • questionnaires survey
    • +3 more
    • Beijing, Beijing, China
      Lei Li
    Jun 19, 2019

    Jejunoileal vs Gastric GIST in the Era of Imatinib.

    Completed
    • Disease-free Survival
    • +2 more
      • Murcia, Spain
        David Ferreras
      Apr 18, 2019

      Tumor Response Rate, Overall Survival Trial in Hangzhou (TILA-TACE treatment)

      Recruiting
      • Tumor Response Rate
      • Overall Survival
      • TILA-TACE treatment
      • Hangzhou, Zhejiang, China
        The Second affiliated Hospital, Zhejiang University School of Me
      Apr 8, 2019

      Overall Survival Trial in Qingdao (Irinotecan,Oxaliplatin, and S1)

      Unknown status
      • Overall Survival
      • Irinotecan,Oxaliplatin, and S1
      • Qingdao, China
        Qingdao Central Hospital
      Oct 29, 2018

      Advanced Prostate Cancer, Lower Urinary Tract Symptoms, Quality of Life Trial (Surgery combinate with Endocrine therapy,

      Not yet recruiting
      • Advanced Prostate Cancer
      • +4 more
      • Surgery combinate with Endocrine therapy
      • Endocrine therapy
      • (no location specified)
      Oct 8, 2018

      Overall Survival in Completely Resected Chinese NSCLC

      Unknown status
      • Overall Survival
        • (no location specified)
        Sep 3, 2018